6-Fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid

We are 6-Fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid CAS:112984-60-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:6-Fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
CAS.NO:112984-60-8
Synonyms:6-Fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
6-Fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 577.0±50.0 °C at 760 mmHg
Molecular Formula C16H16FN3O3S
Molecular Weight 349.380
Flash Point 302.8±30.1 °C
 
Specification:
Appearance:Light yellow to yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Prulifloxacin(CAS:123447-62-1).

6-Fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid


Related News: Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.4,4'-dibromobifenilo CAS:92-86-4 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.1-chloro-2-fluorobenzene CAS:348-51-6 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.1,10-undecadiene CAS:13688-67-0 The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.

Related Products
Product Name
Hydrazine sulfate Cas:10034-93-2 View Details
Glyceryl Monooleate Cas:111-03-5 View Details
Chlorodimethylethylsilane Cas:6917-76-6 View Details
solvent black 7 Cas:8005-02-5 manufacturer LUTETIUM FLUORIDE Cas:13709-42-7 manufacturer 2-Ethylhexyl glycidyl ether manufacturer 2,6-DIPHENYLPHENOL Cas:2432-11-3 manufacturer triethoxy-(2,3,4,5,6-pentafluorophenyl)silane Cas:20083-34-5 manufacturer